No Data
No Data
Pharmaceutical Biotech (02269) spent about HK$498.683 million to buy back 3.49 million shares on March 28
Pharmaceutical Biotech (02269) announced that on March 28, 2024, it cost approximately HK$498.683 million to repurchase 34...
Pharmaceutical Biotech (2269.HK): Commercial production continues to expand, and the number of comprehensive projects is steadily increasing
Event: The company announced its 2023 results, achieving revenue of 17.03 billion yuan (YOY +11.6%); achieving net profit of 3.40 billion yuan (YOY -23.1%) to achieve adjusted net profit of 49.5 billion yuan
Tencent sweeps goods for nearly HK$1.4 billion, selling Meituan over HK$300 million; Nanshui added Wuliangye for nearly 500 million yuan
On March 28 (Thursday), Southbound made a net purchase of HK$3.802 billion in Hong Kong stocks today. Xiaomi Group-W and Bank of China received net purchases of HK$301 million and HK$253 million respectively; China Mobile and Kuaishou-W received net sales of HK$205 million and HK$201 million respectively.
WUXI BIOLOGICS(2269.HK):EXPAND OVERSEAS CAPACITY TO MITIGATE RISKS
WuXi Biologics (Wuxi Bio) reported 2023 revenue of RMB17.03bn, up 11.6% YoY, att
Hong Kong Stock Afternoon Review | The three major indices have risen one after another. The Tech Index has risen by nearly 4%, the Science Network stock and gold stock have risen together, Bilibili has risen more than 9%, and Lingbao Gold has risen nearl
Auto stocks rose more than 5%, and ideally nearly 5%; biotech stocks strengthened, Genting Xinyao rose more than 8%, and Pharmaceutical Biotech rose more than 7%; petroleum stocks rose more than 3%, CNOOC rose more than 2%, and Sinopec rose slightly.
Pharmaceutical Biotech (2269.HK) 2023 Annual Report Review: New global production capacity has been put into operation one after another to achieve steady growth in non-COVID-19 performance
Incident: On March 26, 2024, Yao Ming Biotech released its 2023 annual report. It achieved annual revenue of 17.03 billion yuan, an increase of 11.6% over the previous year. The revenue growth rate for non-COVID-19 projects was 37.7%, and net profit returned to mother
No Data